EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Factor XII—A New Therapeutic Target? A Systematic Review

Katarzyna Krajewska, Joanna Pawlus iD, Katarzyna Ptaszynska iD, Anna Lisowska

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27031331 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Katarzyna Krajewska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Teaching Hospital in Bialystok, Medical University of Bialystok, 15-276 Bialystok, Poland. Hauptthemen laut MEDLINE: Factor XII. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Factor XII is a molecule of unclear physiological function that has attracted increasing research interest across multiple medical disciplines. In recent years, a substantial body of evidence has emerged regarding the contribution of factor XII to the pathogenesis of inflammatory and prothrombotic conditions. FXII has been shown to play a protective role in FXII-driven coagulation during host defence against infections and to protect against multi-organ failure in animal models of sepsis. In acute respiratory distress syndrome (ARDS), FXII activity contributes to the release of pro-inflammatory mediators and is associated with severe clinical outcomes; it also induces fibroblast migration in idiopathic pulmonary fibrosis. FXII deficiency has been associated with reduced neutrophil adhesion and migration in sterile skin wounds and immune complex-induced vasculitis. In neurological conditions, FXII deficiency significantly reduced the number and severity of multiple sclerosis relapses and decreased the volume of post-traumatic brain oedema. In heart failure pathogenesis, FXII deficiency and pharmacological inhibition of FXII activity blocked activation of the renin–angiotensin–aldosterone system (RAAS) in dilated cardiomyopathy, increased median survival, and delayed heart failure onset in murine models. Importantly, FXII inhibition prevented arterial thrombosis without affecting haemostasis. This review summarises the latest findings on the contribution of FXII to inflammatory and prothrombotic states across multiple medical fields, including cardiology. Pharmacological inhibition of FXII has generated considerable interest as a potential future therapeutic strategy; however, to date, human studies remain limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Factor XIIHumansAnimalsBlood CoagulationThrombosisInflammationFactor XII Deficiency

Stichwörter der Autor:innen

FXII factor in heart failureFXII in neuroinflammationfactor FXIIfactor XII in coronary syndromefactor XII in thrombosisfactor in inflammation

Substanzen

Factor XII

Autor:innen und Institutionen

  • Department of Cardiology, Teaching Hospital in Bialystok, Medical University of Bialystok, 15-276 Bialystok, Poland.
  • Department of Haematology Diagnostics, Teaching Hospital in Bialystok, Medical University of Bialystok, 15-276 Bialystok, Poland.

ORCID-Profile: Joanna Pawlus, Katarzyna Ptaszynska

Zitieren

APA

Krajewska, K., Pawlus, J., Ptaszynska, K., & Lisowska, A. (2026). Factor XII—A New Therapeutic Target? A Systematic Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031331

Vancouver

Krajewska K, Pawlus J, Ptaszynska K, Lisowska A. Factor XII—A New Therapeutic Target? A Systematic Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27031331

BibTeX
@article{Krajewska2026,
  author = {Krajewska, Katarzyna and Pawlus, Joanna and Ptaszynska, Katarzyna and Lisowska, Anna},
  title = {Factor XII—A New Therapeutic Target? A Systematic Review},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27031331}
}
Kostenlos starten →